Bajetta Emilio, Catena Laura, Procopio Giuseppe, De Dosso Sara, Bichisao Ettore, Ferrari Leonardo, Martinetti Antonia, Platania Marco, Verzoni Elena, Formisano Barbara, Bajetta Roberto
S.C. Oncologia Medica 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G. Venezian, 1, Milan 20133, Italy.
Cancer Chemother Pharmacol. 2007 Apr;59(5):637-42. doi: 10.1007/s00280-006-0306-6. Epub 2006 Aug 26.
The aim of this trial was to evaluate the safety and efficacy of oxaliplatin and capecitabine (XELOX) in neuroendocrine tumours' (NETs) treatment.
Forty patients (pts) with advanced NETs were treated. Of these, 13 had untreated poorly differentiated NETs, 27 had well-differentiated NETs in progression after somatostatin analogues. Patients received oxaliplatin e.v. 130 mg/mq i.v. and capecitabine 2,000 mg/mq/die. The primary sites of the disease were: lung (10 pts), pancreas (15 pts), small bowel (8 pts), unknown (1 pt), others (6 pts).
In 13 pts with poorly differentiated NETs objective responses (OR) were: 3 PR (23%), 1 SD (7%), 9 PD (70%). Biochemical responses were 11%. In 27 patients with well-differentiated NETs the OR were: 8 PR (30%), 13 SD (48%) and 6 PD (22%). Biochemical and symptomatic responses were 20 and 50%, respectively.
The XELOX regimen is effective and tolerated in well-differentiated NETs after progression following somatostatin analogues.
本试验旨在评估奥沙利铂和卡培他滨（XELOX方案）治疗神经内分泌肿瘤（NETs）的安全性和疗效。
对40例晚期NETs患者进行治疗。其中，13例为未经治疗的低分化NETs，27例为生长抑素类似物治疗后病情进展的高分化NETs。患者接受静脉注射奥沙利铂130mg/m²及卡培他滨2000mg/m²/天。疾病的主要部位为：肺（10例）、胰腺（15例）、小肠（8例）、不明（1例）、其他（6例）。
13例低分化NETs患者的客观缓解（OR）情况为：3例部分缓解（PR，23%），1例疾病稳定（SD，7%），9例疾病进展（PD，70%）。生化缓解率为11%。27例高分化NETs患者的OR情况为：8例PR（30%），13例SD（48%），6例PD（22%）。生化缓解率和症状缓解率分别为20%和50%。
对于生长抑素类似物治疗后病情进展的高分化NETs，XELOX方案有效且耐受性良好。
Zotero 插件